Game-changer for prostate cancer: Veracyte’s test predicts who will benefit from chemo

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced compelling new data from the phase 3 STAMPEDE clinical trial demonstrating that its Decipher ... Read More